Jardiance (Empagliflozin) Patent Expiration, LOE Window & CMS Spending
Jardiance (Empagliflozin) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2029-02-01 (last listed 2034-12-11), 1 AB generics, $13.68B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N204629 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-02-01 |
| Last Listed Patent or Exclusivity Date | 2034-12-11 |
| Orange Book Patents (*PED Extensions) | 27 patents (12 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $13.68B |
| 2024 Medicare Part D Spend | $11.44B |
| 2024 Medicaid Spend | $2.24B |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.